Peripheral molecular signatures of major depressive disorder: a systematic review of blood-derived biomarkers for diagnosis, stratification, and treatment response.
- 1Department of General Medicine, SRM Medical College Hospital and Research Centre, Faculty of Medicine and Health Sciences, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu, Tamilnadu, India.
- 2Department of Pharmacy Practice, SRM College of Pharmacy, Faculty of Medicine and Health Sciences, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu, Tamilnadu, India.
- 3Department of General Medicine, SRM Medical College Hospital and Research Centre, Faculty of Medicine and Health Sciences, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu, Tamilnadu, India. [email protected].
Abstract
Background
Major depressive disorder (MDD) is biologically heterogeneous, yet diagnosis and treatment selection remain largely symptom-based. Blood-derived molecular biomarkers may offer scalable tools for biomarker discovery, biological stratification, and treatment-response research, but their clinical readiness remains uncertain.Methods
This PRISMA-compliant systematic review was registered in PROSPERO (CRD420261379864). PubMed, Scopus, and Embase were searched from 2014 to 27 April 2026 for human studies evaluating blood-derived molecular biomarkers in MDD or clinically defined depressive phenotypes with extractable depression-relevant data. Eligible domains included transcriptomics, DNA methylation, non-coding RNA, immune-inflammatory, mitochondrial/metabolic, neurotrophic/neuroendocrine, multi-omics, and machine-learning biomarker studies. Owing to methodological and platform heterogeneity, a structured narrative synthesis was performed rather than quantitative meta-analysis. Methodological quality was assessed using a modified QUADOMICS framework, prediction-model studies were additionally assessed using PROBAST, and certainty was judged using a modified GRADE approach.Results
Of 9,354 records identified, 25 reports met the eligibility criteria, representing 24 independent participant datasets because two methylation analyses used the same underlying NESDA cohort. Included studies used whole blood, PBMCs, leukocytes, monocytes, serum, plasma, and cell-free RNA across diverse molecular platforms. Individual biomarkers were heterogeneous, but recurrent pathway-level signals involved immune-inflammatory and interferon-related pathways, NF-κB signalling, mitochondrial and energy metabolism, DNA methylation and epigenetic regulation, neurodevelopmental/synaptic pathways, stress-response signalling, autophagy, and non-coding RNA regulation. Multi-marker and multi-omics panels showed promising apparent diagnostic or treatment-response relevance, but most were internally validated, cohort-specific, or exploratory. Modified GRADE certainty was low to very low across biomarker domains.Conclusions
Blood-derived molecular signatures in MDD show stronger convergence at the pathway level than at the individual-biomarker level. Current evidence supports hypothesis generation and biological stratification, but no blood-derived biomarker or panel is ready for routine diagnosis or treatment selection.
Related
- Peripheral immune biomarkers, brain imaging phenotypes and treatment response in major depressive disorder
- Circulating calprotectin and S100A8/A9-related biomarkers for diagnosis and prognostic stratification in adult acute infection and sepsis: a systematic review and meta-analysis.
- Cortical hemodynamic dysregulation is linked to peripheral NIMETOX pathways in major depressive disorder: an 89-channel fNIRS systems-biology study.
- Toward Precision Colorectal Cancer Screening: Integrating Clinical Risk Stratification, Molecular Biomarkers, and Artificial Intelligence
- Core needle biopsy washout biomarkers combined with ultrasound for preoperative axillary risk stratification in breast cancer: a retrospective nomogram study with temporal validation
BibTeX
@article{jayanth2026peripheral,
title = {{Peripheral molecular signatures of major depressive disorder: a systematic review of blood-derived biomarkers for diagnosis, stratification, and treatment response.}},
author = {M S Jayanth and G Sindhu and Hariharan Murugadoss and Mohammed Fayaz Sadiqbasha and T A Vidya and Sudhagar Mookappan},
journal = {BMC psychiatry},
year = {2026},
month = aug,
doi = {10.1186/s12888-026-08450-x},
url = {https://europepmc.org/article/MED/42968091},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Peripheral molecular signatures of major depressive disorder: a systematic review of blood-derived biomarkers for diagnosis, stratification, and treatment response.
AU - M S Jayanth
AU - G Sindhu
AU - Hariharan Murugadoss
AU - Mohammed Fayaz Sadiqbasha
AU - T A Vidya
AU - Sudhagar Mookappan
PY - 2026
DA - 2026/08/05
JO - BMC psychiatry
DO - 10.1186/s12888-026-08450-x
UR - https://europepmc.org/article/MED/42968091
AB - Background Major depressive disorder (MDD) is biologically heterogeneous, yet diagnosis and treatment selection remain largely symptom-based. Blood-derived molecular biomarkers may offer scalable tools for biomarker discovery, biological stratification, and treatment-response research, but their clinical readiness remains uncertain.Methods This PRISMA-compliant systematic review was registered in PROSPERO (CRD420261379864). PubMed, Scopus, and Embase were searched from 2014 to 27 April 2026 for human studies evaluating blood-derived molecular biomarkers in MDD or clinically defined depressive phenotypes with extractable depression-relevant data. Eligible domains included transcriptomics, DNA methylation, non-coding RNA, immune-inflammatory, mitochondrial/metabolic, neurotrophic/neuroendocrine, multi-omics, and machine-learning biomarker studies. Owing to methodological and platform heterogeneity, a structured narrative synthesis was performed rather than quantitative meta-analysis. Methodological quality was assessed using a modified QUADOMICS framework, prediction-model studies were additionally assessed using PROBAST, and certainty was judged using a modified GRADE approach.Results Of 9,354 records identified, 25 reports met the eligibility criteria, representing 24 independent participant datasets because two methylation analyses used the same underlying NESDA cohort. Included studies used whole blood, PBMCs, leukocytes, monocytes, serum, plasma, and cell-free RNA across diverse molecular platforms. Individual biomarkers were heterogeneous, but recurrent pathway-level signals involved immune-inflammatory and interferon-related pathways, NF-κB signalling, mitochondrial and energy metabolism, DNA methylation and epigenetic regulation, neurodevelopmental/synaptic pathways, stress-response signalling, autophagy, and non-coding RNA regulation. Multi-marker and multi-omics panels showed promising apparent diagnostic or treatment-response relevance, but most were internally validated, cohort-specific, or exploratory. Modified GRADE certainty was low to very low across biomarker domains.Conclusions Blood-derived molecular signatures in MDD show stronger convergence at the pathway level than at the individual-biomarker level. Current evidence supports hypothesis generation and biological stratification, but no blood-derived biomarker or panel is ready for routine diagnosis or treatment selection.
SN - 1471-244X
ER -